Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals Announces Restructuring of Commercial Organization
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals to Present at Upcoming Investor Conferences
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH™ for the Treatment of Common Warts
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH™
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals’ Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals Announces Presentation at the Jefferies Global Healthcare Conference in London
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 9, 2023
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals to Host Virtual KOL Event Discussing the Approval of YCANTH™ (Cantharidin) Topical Solution for the Treatment of Molluscum on October 11, 2023
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals Announces First Sale of YCANTH™ to FFF Enterprises
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Issues Statement in Support of FDA’s Warning Letters to Manufacturers and Retailers for Producing and Selling Unapproved Products for the Treatment of Molluscum Contagiosum
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.